keyword
MENU ▼
Read by QxMD icon Read
search

baclofen AND alcohol

keyword
https://www.readbyqxmd.com/read/29897022/can-baclofen-change-alcohol-related-cognitive-biases-and-what-is-the-role-of-anxiety-herein
#1
Esther M Beraha, Elske Salemink, Erwin Krediet, Reinout W Wiers
BACKGROUND: Baclofen has shown promise in the treatment of alcohol dependence. However, its precise (neuro-) psychological working mechanism is still under debate. AIMS: This study aimed to get a better understanding of baclofen's working mechanism by examining the effect of baclofen on cognitive biases. It was hypothesized that baclofen, compared to placebo, would lead to weaker cognitive biases. Furthermore, given a suggested anxiolytic effect of baclofen, we expected that anxiety would moderate this effect...
June 1, 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29888478/baclofen-for-alcohol-use-disorder-a-systematic-meta-analysis
#2
T Bschor, J Henssler, M Müller, C Baethge
OBJECTIVE: To evaluate the efficacy and tolerability of baclofen vs. placebo for long-term treatment of alcohol use disorder. METHOD: Systematic review and meta-analysis following methods of the Cochrane Collaboration Handbook (PROSPERO registration: CRD42017073663). Primary outcome was the random-effects summary estimate of all standardized mean differences (SMDs), as calculated from the primary outcomes of each study. RESULTS: Fourteen double-blind RCTs (1522 patients) were included...
June 10, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29788886/novel-pharmacotherapeutic-approaches-in-treatment-of-alcohol-addiction
#3
Rashidi Mohamed Pakri Mohamad, Jaya Kumar, Shihab Udin Ahmad, Isa Naina Mohamed
In the past two decades, the search for novel pharmacotherapies to treat alcohol addiction been a global endeavour. This has resulted in several drugs that have been approved and successfully marketed for public use while some are still in the testing phase. These pharmacological agents, though effective for the treatment of alcoholism, are not without shortcomings; such as abuse potential, serious mental and physical adverse effects, interaction with alcohol and also poor metabolism and excretion. As more is being understood about the neurobiology of alcohol addiction as well as the unique pharmacological action of these drugs, new agents are evaluated for potential benefits when used as a adjunct in combination therapy...
May 22, 2018: Current Drug Targets
https://www.readbyqxmd.com/read/29782961/baclofen-induced-encephalopathy-in-overdose-modeling-of-the-electroencephalographic-effect-concentration-relationships-and-contribution-of-tolerance-in-the-rat
#4
Magali Chartier, Isabelle Malissin, Salma Tannous, Laurence Labat, Patricia Risède, Bruno Mégarbane, Lucie Chevillard
Baclofen, a γ-amino-butyric acid type-B receptor agonist with exponentially increased use at high-dose to facilitate abstinence in chronic alcoholics, is responsible for increasing poisonings. Baclofen overdose may induce severe encephalopathy and electroencephalographic (EEG) abnormalities. Whether prior prolonged baclofen treatment may influence the severity of baclofen-induced encephalopathy in overdose has not been established. We designed a rat study to characterize baclofen-induced encephalopathy, correlate its severity with plasma concentrations and investigate the contribution of tolerance...
May 18, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29719204/drug-drug-interactions-in-the-treatment-for-alcohol-use-disorders-a-comprehensive-review
#5
REVIEW
Guerzoni Simona, Pellesi Lanfranco, Pini Luigi Alberto, Caputo Fabio
Drug interactions are one of the most common causes of side effects in polypharmacy. Alcoholics are a category of patients at high risk of pharmacological interactions, due to the presence of comorbidities, the concomitant intake of several medications and the pharmacokinetic and pharmacodynamic interferences of ethanol. However, the data available on this issue are limited. These reasons often frighten clinicians when prescribing appropriate pharmacological therapies for alcohol use disorder (AUD), where less than 15% of patients receive an appropriate treatment in the most severe forms...
April 29, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29716670/baclofen-in-the-treatment-of-alcohol-dependence-with-or-without-liver-disease-multisite-randomised-double-blind-placebo-controlled-trial
#6
Kirsten C Morley, Andrew Baillie, Isabel Fraser, Ainsley Furneaux-Bate, Glenys Dore, Michael Roberts, Ahmed Abdalla, Nghi Phung, Paul S Haber
BACKGROUND: There are no available medications for the management of alcohol dependence for patients with alcoholic liver disease (ALD).AimsTo conduct a multisite, double blind, placebo-controlled, randomised clinical trial of baclofen in the treatment of alcohol dependence, with or without liver disease (trial registration: ClinicalTrials.gov, NCT01711125). METHOD: Patients (n = 104) were randomised to placebo, baclofen 30 mg/day or 75 mg/day for 12 weeks. Primary outcomes included survival time to lapse (any drinking), relapse (≥5 drinks per day in men and ≥4 in women), and the composite outcome of drinks per drinking day, number of heavy drinking days, and percentage days abstinent...
June 2018: British Journal of Psychiatry: the Journal of Mental Science
https://www.readbyqxmd.com/read/29665351/neuroendocrine-response-to-gaba-b-receptor-agonism-in-alcohol-dependent-individuals-results-from-a-combined-outpatient-and-human-laboratory-experiment
#7
Mehdi Farokhnia, Mikela B Sheskier, Mary R Lee, April N Le, Erick Singley, Sofia Bouhlal, Timmy Ton, Zhen Zhao, Lorenzo Leggio
Gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the nervous system, plays an important role in biobehavioral processes that regulate alcohol seeking, food intake, and stress response. The metabotropic GABA-B receptor has been investigated as a potential therapeutic target for alcohol use disorder, by using orthosteric agonists (e.g., baclofen) and positive allosteric modulators. Whether and how pharmacological manipulation of the GABA-B receptor, in combination with alcohol intake, may affect feeding- and stress-related neuroendocrine pathways remains unknown...
April 14, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29651507/efficacy-and-side-effects-of-baclofen-and-the-novel-gaba-b-receptor-positive-allosteric-modulator-cmppe-in-animal-models-for-alcohol-and-cocaine-addiction
#8
Valentina Vengeliene, Tatiane T Takahashi, Olga A Dravolina, Irina Belozertseva, Edwin Zvartau, Anton Y Bespalov, Rainer Spanagel
RATIONALE: Preclinical studies suggest that the GABAB receptor is a potential target for treatment of substance use disorders. However, recent clinical trials report adverse effects in patients treated with the GABAB receptor agonist baclofen and even question efficacy. How can the discrepancy between preclinical and clinical findings be explained? OBJECTIVE: To test efficacy and adverse effects of baclofen and the novel GABAB positive allosteric modulator (PAM) CMPPE in rat addiction models, which were developed in accordance with DSM...
April 12, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29589877/an-observational-study-of-benzodiazepine-prescription-during-inpatient-alcohol-detoxification-for-patients-with-versus-without-chronic-pretreatment-with-high-dosage-baclofen
#9
EDITORIAL
https://www.readbyqxmd.com/read/29567624/functional-inactivation-of-the-orbitofrontal-cortex-disrupts-context-induced-reinstatement-of-alcohol-seeking-in-rats
#10
Paula Cristina Bianchi, Paulo Eduardo Carneiro de Oliveira, Paola Palombo, Rodrigo Molini Leão, Hugo Cogo-Moreira, Cleopatra da Silva Planeta, Fábio Cardoso Cruz
BACKGROUND: The high rate of relapse to drug use remains a central challenge to treating drug addiction. In human and rat models of addiction, environmental stimuli in contexts associated with previous drug use can provoke a relapse of drug seeking. Pre-clinical studies have used the ABA renewal procedure to study context-induced reinstatement of drug seeking. In the current study, we studied the role of the orbitofrontal cortex (OFC) in context-induced reinstatement to alcohol. METHODS: We trained male and female rats to self-administer alcohol in context A, extinguished drug-reinforced responding in a distinct context B, and assessed context-induced reinstatement in context A or B (control group)...
May 1, 2018: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29483088/baclofen-is-largely-ineffective-for-alcohol-use-disorders-finds-study
#11
Susan Mayor
No abstract text is available yet for this article.
February 26, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29479827/baclofen-its-effectiveness-in-reducing-harmful-drinking-craving-and-negative-mood-a-meta-analysis
#12
REVIEW
Abigail K Rose, Andrew Jones
BACKGROUND AND AIMS: There are a limited number of pharmacotherapies licensed for alcohol use disorders (AUDs). Baclofen is a γ-aminobutyric acid B (GABA-B) agonist which is used increasingly as an off-label treatment. A meta-analysis of randomized controlled trials (RCTs) was conducted to determine the efficacy of baclofen in reducing drinking behaviour, craving, depression and anxiety compared with placebo. METHODS: Random-effects meta-analyses were computed on outcome data from 12 RCTs comparing baclofen with placebo...
February 26, 2018: Addiction
https://www.readbyqxmd.com/read/29359279/hypothalamic-pituitary-adrenocortical-axis-activity-in-alcohol-dependent-patients-during-treatment-with-high-dose-baclofen
#13
Olga Geisel, Ludwig Schlemm, Rainer Hellweg, Klaus Wiedemann, Christian A Müller
AIMS: Activity of the hypothalamic-pituitary-adrenocortical (HPA) axis has been reported to be affected in alcohol use disorder (AUD). It has been suggested that pharmacological relapse prevention in AUD might exert its effects partly by modulation of HPA axis activity. Here, we assessed the effects of high-dose treatment with baclofen on HPA axis activity in alcohol-dependent patients within a 24-week randomized, placebo-controlled trial (BACLAD study). METHODS: Plasma levels of copeptin, adrenocorticotropic hormone (ACTH), and cortisol were measured at 3 timepoints in alcohol-dependent patients during the study...
January 22, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29224234/an-observational-study-of-benzodiazepine-prescription-during-inpatient-alcohol-detoxification-for-patients-with-vs-without-chronic-pretreatment-with-high-dosage-baclofen
#14
Laura Martinez, Florence Vorspan, Xavier Declèves, Julien Azuar, Maeva Fortias, Franck Questel, Alexandra Dereux, Leslie Grichy, Hélène Barreteau, Frank Bellivier, Jean-Pierre Lépine, Vanessa Bloch
High-dose baclofen is prescribed as a maintenance treatment to reduce alcohol use in patients with alcohol use disorder. Nevertheless, some patients still have massive alcohol intakes and require inpatient alcohol withdrawal. To compare the oral dose of benzodiazepine prescribed to manage alcohol withdrawal symptoms in patients with vs. without steady-state pretreatment with high-dose baclofen. Retrospective chart review study. Prescribed benzodiazepine dose expressed in diazepam-equivalent was compared between groups...
April 2018: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29143356/on-the-ground-application-of-the-temporary-recommendation-for-use-regulatory-measure-on-off-label-use-of-baclofen-for-alcohol-dependence-in-france-a-regional-survey-of-community-pharmacies
#15
Marine Auffret, Benjamin Rolland, Anne-Sylvie Caous, Louise Gaboriau, Sylvie Deheul, Régis Bordet, Sophie Gautier
The 'temporary recommendation for use' (TRU) is a French novel regulatory measure for off-label drug. The first TRU to be issued by the French drug agency (in March 2014) pertained to the off-label use of baclofen for alcohol dependence (AD). We performed a questionnaire-based survey of the on-the-ground application of the baclofen TRU among community pharmacies in northern France. A pharmacist from 70 of the 219 pharmacies contacted (response rate: 32.0%) completed the questionnaire. The mean ± standard deviation number of off-label baclofen prescriptions for AD was 2...
April 2018: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29120249/alcohol-addiction-the-safety-of-available-approved-treatment-options
#16
REVIEW
Mariangela Antonelli, Anna Ferrulli, Luisa Sestito, Gabriele A Vassallo, Claudia Tarli, Carolina Mosoni, Maria M Rando, Antonio Mirijello, Antonio Gasbarrini, Giovanni Addolorato
Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a 'temporary recommendation for use' in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed...
February 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29091319/population-pharmacokinetics-of-oral-baclofen-at-steady-state-in-alcoholic-dependent-adult-patients
#17
Lucie Chevillard, Naomi Sabo, Michel Tod, Laurence Labat, Céline Chasport, Céline Chevaleyre, Florence Thibaut, Jérôme Barré, Julien Azuar, Franck Questel, Florence Vorspan, Vanessa Bloch, Frank Bellivier, Bernard Granger, Camille Barrault, Xavier Declèves
Baclofen has been proposed for few years to help treating alcohol dependence at higher doses than those used in neurology. Baclofen pharmacokinetics has been previously well described at low oral or intravenous doses but remains poorly investigated with such high oral doses. We here describe dose regimens of baclofen in 143 alcohol-dependent patients treated with steady-state oral doses of baclofen. Plasma baclofen levels were measured in blood samples using liquid chromatography coupled with tandem mass spectrometry...
April 2018: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29050951/microinjection-of-baclofen-and-cgp7930-into-the-ventral-tegmental-area-suppresses-alcohol-self-administration-in-alcohol-preferring-rats
#18
REVIEW
Paola Maccioni, Irene Lorrai, Andrea Contini, Kimberly Leite-Morris, Giancarlo Colombo
Systemic administration of the orthosteric agonist, baclofen, and several positive allosteric modulators (PAMs) of the GABAB receptor has repeatedly been reported to decrease operant oral alcohol self-administration in rats. The aim of the present study was to evaluate the contribution of the mesolimbic dopamine system to the reducing effect of baclofen and GABAB PAMs on the reinforcing properties of alcohol. To this end, baclofen or the GABAB PAM CGP7930 were microinjected into the ventral tegmental area (VTA) of selectively bred, Sardinian alcohol-preferring (sP) rats trained to self-administer alcohol...
October 16, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29036310/baclofen-self-poisoning-in-the-era-of-changing-indication-multicentric-reports-to-a-french-poison-control-centre
#19
Maxime Léger, Marion Brunet, Gaël Le Roux, Nicolas Lerolle, David Boels
Aims: Baclofen has gained interest in treating alcohol use disorder patients. These patients are at risk of voluntary drug intoxications. Understanding the context of baclofen's widespread use for alcohol use disorder, a recent evaluation of the epidemiology, morbidity and mortality of baclofen self-poisoning episodes is necessary. Methods: All baclofen self-poisoning reported to the Western France Poison Control Centre between January 2008 and December 2015 were included for analysis in this retrospective study...
November 1, 2017: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/28967184/lc-ms-ms-method-for-quantification-of-baclofen-in-hair-a-useful-tool-to-assess-compliance-in-alcohol-dependent-patients
#20
I A Larabi, N Fabresse, A Knapp, M Forcet, F J Baud, G Lorin de la Grandmaison, J C Alvarez
To evaluate adherence to treatment, we developed and validated a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for baclofen quantification in hair.Twenty mg was washed twice with dichloromethane, incubated in phosphate buffer (pH 5) for 10 minutes at 95°C, then extracted by liquid-liquid extraction in alkaline condition. Baclofen-d4 was used as the internal standard. This method was applied to assess compliance in4 treated alcohol-dependent patients (3 dead and one living). Blood quantification of baclofen and ethanol were performed in the 4 cases...
April 2018: Drug Testing and Analysis
keyword
keyword
86358
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"